Dashboard
Manage Tickers

GH


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

piper-sandler-maintains-overweight-on-guardant-health-raises-price-target-to-90
Piper Sandler Maintains Overweight on Guar...
10/22/2025 15:08:40

Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target f...

is-guardant-health-inc-gaining-or-losing-market-support
Is Guardant Health Inc Gaining or Losing M...
10/21/2025 18:00:35

guardant-health-to-present-new-data-from-across-its-oncology-portfolio-in-15-accepted-abstracts-at-the-european-society-for-medical-oncology-congress-2025-taking-place-october-1721-in-berlin-germany-presentations-highlight-the-power-of-guardant-healths-blood-based-assays-to-reduce-treatment-burden-and-improve-disease-monitoring-across-multiple-cancer-types
Guardant Health To Present New Data From A...
10/15/2025 21:01:15

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that new data from across its oncology...

evercore-isi-group-maintains-outperform-on-guardant-health-raises-price-target-to-68
Evercore ISI Group Maintains Outperform on...
10/07/2025 17:22:48

Evercore ISI Group analyst Daniel Markowitz maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price tar...

what-does-the-market-think-about-guardant-health-inc
What Does the Market Think About Guardant ...
10/03/2025 18:01:13

Core News & Articles
FDA Approves Guardant360 CDx As Companion ...
09/29/2025 12:19:46

This marks the second FDA-approved indication for Guardant360 CDx as a companion diagnostic in breast cancer treatmentESR1 muta...

td-cowen-maintains-buy-on-guardant-health-raises-price-target-to-72
TD Cowen Maintains Buy on Guardant Health,...
09/25/2025 17:52:52

TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ: GH) with a Buy and raises the price target from $63 to $72.

stifel-maintains-buy-on-guardant-health-raises-price-target-to-70
Stifel Maintains Buy on Guardant Health, R...
09/25/2025 17:06:08

Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ: GH) with a Buy and raises the price target from $60 to $70.

leerink-partners-maintains-outperform-on-guardant-health-raises-price-target-to-75
Leerink Partners Maintains Outperform on G...
09/25/2025 16:44:30

Leerink Partners analyst Puneet Souda maintains Guardant Health (NASDAQ: GH) with a Outperform and raises the price target f...

mizuho-maintains-outperform-on-guardant-health-raises-price-target-to-70
Mizuho Maintains Outperform on Guardant He...
09/25/2025 16:30:17

Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ: GH) with a Outperform and raises the price target from $65...

wolfe-research-upgrades-guardant-health-to-outperform-announces-75-price-target
Wolfe Research Upgrades Guardant Health to...
09/25/2025 15:47:45

Wolfe Research analyst Doug Schenkel upgrades Guardant Health (NASDAQ: GH) from Peer Perform to Outperform and announces $75...

ubs-maintains-buy-on-guardant-health-raises-price-target-to-80
UBS Maintains Buy on Guardant Health, Rais...
09/25/2025 15:18:20

UBS analyst Dan Leonard maintains Guardant Health (NASDAQ: GH) with a Buy and raises the price target from $70 to $80.

guggenheim-maintains-buy-on-guardant-health-raises-price-target-to-67
Guggenheim Maintains Buy on Guardant Healt...
09/25/2025 12:54:31

Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ: GH) with a Buy and raises the price target from $56 to $67.

jp-morgan-maintains-overweight-on-guardant-health-raises-price-target-to-70
JP Morgan Maintains Overweight on Guardant...
09/25/2025 12:48:40

JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ: GH) with a Overweight and raises the price target from $...

btig-maintains-buy-on-guardant-health-raises-price-target-to-80
BTIG Maintains Buy on Guardant Health, Rai...
09/25/2025 12:09:20

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ: GH) with a Buy and raises the price target from $70 to $80.

Core News & Articles
Guardant Health And Quest Diagnostics Coll...
09/24/2025 12:19:19

Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest&...

wells-fargo-initiates-coverage-on-guardant-health-with-overweight-rating-announces-price-target-of-72
Wells Fargo Initiates Coverage On Guardant...
09/22/2025 12:50:10

Wells Fargo analyst Brandon Couillard initiates coverage on Guardant Health (NASDAQ:GH) with a Overweight rating and announc...

btig-reiterates-buy-on-guardant-health-maintains-70-price-target
BTIG Reiterates Buy on Guardant Health, Ma...
09/22/2025 10:42:32

BTIG analyst Mark Massaro reiterates Guardant Health (NASDAQ:GH) with a Buy and maintains $70 price target.

btig-maintains-buy-on-guardant-health-raises-price-target-to-70
BTIG Maintains Buy on Guardant Health, Rai...
09/04/2025 16:10:00

BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $65 to $70.

guardant-healths-updated-shield-v2-blood-test-shows-84-sensitivity-90-specificity-for-colorectal-cancer-detection-in-eclipse-study
Guardant Health's Updated Shield V2 Blood ...
09/04/2025 12:08:28

Latest algorithm (Shield V2) has sensitivity of 84% for colorectal cancer with specificity of 90%, with stage I sensitivity of ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION